Congenica is a Biotechnology company. It has raised $82M in total funding. Latest round: Series C.
Congenica funding overview
Congenica is a Biotechnology company. Congenica has raised $82M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in November 2020. The round record for Congenica runs through 2020; nothing later has been disclosed. Investors on record include Cambridge Innovation Capital, Amadeus Capital Partners, Sanford Health. 3 distinct backers are named across the disclosed rounds.
Congenica at a glance
Total raised
$82M
Latest round
Series C
Latest round date
November 2020
Industry
Biotechnology
Notable investors
Cambridge Innovation Capital, Amadeus Capital Partners, Sanford Health
Frequently asked about Congenica funding
How much has Congenica raised?
Congenica has raised $82M in total disclosed funding across the rounds on record.
Who has invested in Congenica?
Cambridge Innovation Capital, Amadeus Capital Partners, Sanford Health are named among the investors backing Congenica.
What was the latest Congenica funding round?
The most recent disclosed round is a Series C, announced in November 2020.
Where is Congenica based?
No headquarters location is disclosed for Congenica.
What sector does Congenica operate in?
Congenica is tracked under Biotechnology, with $82M in disclosed funding.
When did Congenica last raise?
The last disclosed Congenica round closed in November 2020 at Series C.
Congenica totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotechnology companies below to benchmark round size and investor mix.
